EBV-associated T/NK-cell Lymphoproliferative Diseases

1

Review clinical trials related to EBV-associated T/NK-cell Lymphoproliferative Diseases. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic Lymphohistiocytosis

This study investigates the impact of letermovir prophylaxis on viral infections (including CMV, EBV, BKV, HHV-6/7, RSV, ADV, HSV, etc.) following allogeneic hematopoietic stem cell transplantation in pediatric patients with EBV-associated T/NK-cell lymphoproliferative diseases and refractory/relapsed EBV-related hemophagocytic lymphohistiocytosis. Additionally, we examine its effects on other transplantation complications, including engraftment failure, graft-versus-host disease (GvHD), disease relapse, thrombotic microangiopathy (TMA), overall survival (OS), post-transplant lymphoproliferative disorder (PTLD) incidence, and immune reconstitution.

Participants needed: 80
Trial details
Age: Up to 18Biological sex: AllType: InterventionalSponsor: Beijing Children's HospitalUpdated: Mar 23, 2026Locations: 1
Eligibility criteria

Diagnosed with EBV-positive T/NK lymphoproliferative disease (EBV-T/NK LPD) acco... [+4]

History of CMV end-organ disease within 6 months prior to enrollment; [+8]